SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.
Company Details
- Employees
- 4
- Address
- Manager Jobs
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://scisparc.com/
- Keywords
- New York.
Scisparc Questions
Scisparc's website is https://scisparc.com/
Scisparc's LinkedIn profile is https://www.linkedin.com/company/scisparc
Scisparc has
4 employees.
View email and phone details for 4
employees at Scisparc.
Scisparc's industry is
Biotechnology Research
Scisparc's top competitors are
Novocure,
Nucleotech,
Kadimastem Ltd.,
Pure Edge,
Evogene,
Aegis Capital Corp.,
Icecure Medical,
Clearmind Medicine,
Prilenia,
Firefly Neuroscience.
Scisparc's categories are Biotechnology Research
